Vote No to the Vaxart Reverse Spilt

A 1-for-20 consolidation shrinks your shares, opens the door to massive dilution, and silences retail holders.

What you need to know

FAQ 1: What is Vaxart proposing?

Vaxart’s board is asking shareholders to approve a reverse stock split of up to 1-for-20. This would reduce the number of shares you own — while keeping their voting and dilution power intact.

FAQ 2: Why are shareholders voting NO?

Because this split would shrink our holdings, then allow the board to issue up to 100 million new shares. That opens the door to severe dilution — without addressing the root issues harming shareholder value.

FAQ 3: Has this happened before?

Yes. In prior years, Vaxart made promises to improve transparency and shareholder relations, but those promises went unfulfilled. Many believe this reverse split is another move that benefits insiders more than investors.

FAQ 4: What happens if the split is rejected?

The company would need to explore alternative ways to meet compliance or raise funds — ideally with more accountability to shareholders. A NO vote keeps power where it belongs: with you.

Digging Deeper

What this means for you

  • Temporarily — but it doesn’t create real value. Reverse splits often lead to short-term price spikes, followed by longer-term declines, especially when accompanied by dilution.

  • Dilution happens when new shares are issued. It reduces your ownership percentage, voting power, and future profit per share. The board has already approved 100 million new shares — this split just makes it easier to sell them.

  • No. This is an independent, shareholder-led effort. We have no ties to Vaxart’s management or board. We believe in transparency, accountability, and protecting retail investors.

  • Yes. Every vote counts — especially when insiders rely on low participation to pass proposals quietly. A large NO turnout from everyday investors sends a message they can’t ignore.